CyberKnife for Unresectable Renal Tumors

Completed · Not applicable

Conditions studied: Renal Cancer

In brief

This is a dose escalation study using the CyberKnife radiotherapy device for small surgical or medically untreatable renal tumors. Patients with renal tumors 5cms or less in diameter will be accrued onto this study. The ability of CyberKnife to ablate these renal tumors and maintain renal function with dose escalation will be assessed.

Key facts

Study ID

NCT00807339

Run by

Beth Israel Deaconess Medical Center

People needed

17

Starts

2006-03-01

Expected to finish

2014-08-20

Last updated by the study team

2017-03-21

Who can join

Age: 18 and older, up to 95. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Tumor size 5 cm or less
• Radiographic evidence of malignancy or Histologically verified primary renal malignancy.
• If the kidney biopsy is inconclusive but the radiologist determines that the tumor based on the CT/MRI is highly suspicious for cancer, you may participate
• Patients with highly suspicious lesions on CT or MRI
• One -three gold fiducials placed in or around tumor
• Contradiction or patient refusal to partial or complete nephrectomy
• Age 18 or greater
• KPS score 70 or greater

You may not qualify if…

• Irreversible coagulopathies that preclude fiducial placement

Where it is running

• Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.